fbpx

An antidote to the politics of the human gene patenting debate

The following contribution to our gene patenting symposium comes from Kevin Noonan, a partner at McDonnell Boehnen Hulbert & Berghoff LLP. It is one of the misfortunes of the human gene patenting debate that there has been precious little discussion of patent law (at least from those opposing gene patents).  Admittedly, patent law is an …

An antidote to the politics of the human gene patenting debate Read More »

Questions that will remain unanswered from the Myriad case

Posted Wed, February 6th, 2013 10:38 am by Robert Cook-Deegan The following contribution to our gene patenting symposium comes from Robert Cook-Deegan, Research Professor, Institute for Genome Sciences & Policy and Sanford School of Public Policy, Duke University.  Association for Molecular Pathology v. Myriad Genetics is not your usual patent lawsuit.  I come to it …

Questions that will remain unanswered from the Myriad case Read More »

The “runcible” product of nature doctrine

The following contribution to our gene patenting symposium comes from Dan L. Burk, Chancellor’s Professor and founding faculty member at the University of California, Irvine School of Law. In April the Court will hear oral argument in Association for Molecular Pathology v. Myriad Genetics on the single question, “Are human genes patentable?”  At issue in …

The “runcible” product of nature doctrine Read More »

Patentable subject matter at the Supreme Court: An exceptional case?

The following contribution to our gene patenting symposium comes from Arti K. Rai, Elvin R. Latty Professor of Law, Duke Law School and Duke Institute for Genome Sciences & Policy.  From 2009-2010, Rai served as the USPTO Administrator for Policy and External Affairs. In three of the past four Terms, the Supreme Court has taken …

Patentable subject matter at the Supreme Court: An exceptional case? Read More »

YouTube
LinkedIn
LinkedIn
Share